Vindesine, a vinca alkaloid derived from vinblastine, has been examined for activity against
a variety of solid and hematological malignancies. Single-agent response rates average …

SUMMARY A broad phase II study of vindesine was conducted in 79 adults with advanced
malignancies. Most patients had solid tumors, particularly adenocarcinomas (59%), and 67 …

Vindesine (VDS) is an analogue of the vinca alkaloids. Its spectrum of antitumoral activity is
similar to that of vincristine (VCR), but with milder experimental neurotoxicity, and it inhibits …

Vindesine is a new vinca alkaloid with broadspectrum antineoplastic activity in experimental
tumor models. Phase-I studies have shown that a weekly dosage regimen of 3–4 mg/m 2 IV …

Vindesine, a newer vinca alkaloid derivative, underwent a phase I clinical evaluation in 68
humans with advanced, refractory malignancies. Patients received single total doses …

A late Phase II clinical trial of vindesine was undertaken to determine its efficacy in patients
with all types of malignancies who had already failed prior treatment. As part of the study an …

Vindesine has useful activity in lung and esophageal cancer. Its use in polychemotherapy
regimes as initial chemotherapy in these conditions is being explored. Vindesine also has …

Vindesine is a new vinca alkaloid antineoplastic agent derived from vinblastine. However, its
antineoplastic spectrum more closely resembles that of vincristine. Clinical studies indicate …

Fifty-six patients with advanced metastatic carcinoma of the breast, melanoma and
lymphoma were treated with the new vinca alkaloid vindesine in a prospective Phase II …

The vinca alkaloids have been found to have activity against a variety of solid tumors,
although they are most active against hematological malignancies. Activity has been …